BioMarin Q2 revenue up 20% to $990M; GAAP EPS $0.23 vs $1.23; raises VOXZOGO guidance

BIOMARIN PHARMACEUTICAL INC

Total revenues $990M (+20% YoY); GAAP net income $45M ($0.23 diluted EPS) vs $241M ($1.23) in Q2 2025.
Non-GAAP income $236M ($1.20 diluted EPS) vs $282M ($1.44) in prior year, down 16%.
VOXZOGO revenue $253M (+14% YoY); full-year guidance raised to at least $1B.
Amicus acquisition closed April 27; cost synergies of ~$280M GAAP / ~$220M non-GAAP expected fully realized by 2028.
Pipeline: sNDA submitted for VOXZOGO in hypochondroplasia; BMN 401 discontinued after Phase 3 miss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.